HRP20180327T1 - Sredstva za uporabu u slučaju intolerancije na fruktozu - Google Patents

Sredstva za uporabu u slučaju intolerancije na fruktozu Download PDF

Info

Publication number
HRP20180327T1
HRP20180327T1 HRP20180327TT HRP20180327T HRP20180327T1 HR P20180327 T1 HRP20180327 T1 HR P20180327T1 HR P20180327T T HRP20180327T T HR P20180327TT HR P20180327 T HRP20180327 T HR P20180327T HR P20180327 T1 HRP20180327 T1 HR P20180327T1
Authority
HR
Croatia
Prior art keywords
fructose
use according
dehydrogenase
fructose dehydrogenase
intolerance
Prior art date
Application number
HRP20180327TT
Other languages
English (en)
Inventor
Daniel Henry Wyrobnik
Isaac Harry Wyrobnik
Elliad Ronen Silcoff
Original Assignee
Pro Natura Gesellschaft für gesunde Ernährung mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006012244A external-priority patent/DE102006012244A1/de
Priority claimed from DE102006013624A external-priority patent/DE102006013624B4/de
Application filed by Pro Natura Gesellschaft für gesunde Ernährung mbH filed Critical Pro Natura Gesellschaft für gesunde Ernährung mbH
Publication of HRP20180327T1 publication Critical patent/HRP20180327T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01124—Fructose 5-dehydrogenase (NADP+) (1.1.1.124)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01026—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/01—Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
    • C12Y503/01005—Xylose isomerase (5.3.1.5)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (17)

1. 5-D-fruktoza dehidrogenaza za uporabu u medicini.
2. 5-D-fruktoza dehidrogenaza za upotrebu prema patentnom zahtjevu 1, naznačena time, da je 5-D-fruktoza dehidrogenaza za upotrebu u terapeutskom tretmanu tijela čovjeka ili životinje.
3. 5-D-fruktoza dehidrogenaza za upotrebu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time, da je uporaba, uporaba u terapiji poremećaja metabolizma fruktoze.
4. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 3, naznačena time, da je poremećaj metabolizma fruktoze nedostatak fruktoze 1,6 difosfataze.
5. 5-D-fruktoza dehidrogenaza za upotrebu u terapiji netolerancije fruktoze.
6. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 5, naznačena time, da je netolerancija fruktoza nasljedna netolerancija fruktoze.
7. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 5, naznačena time, da je netolerancija fruktoze intolerancija crijevne fruktoze.
8. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 7, naznačena time, da je netolerancija fruktoza uzrokovana poremećajem resorpcije fruktoze kao rezultat oštećenja transportnih procesa u sluznici tankog crijeva.
9. 5-D-fruktoza dehidrogenaza za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačena time što je 5-D-fruktoza dehidrogenaza u kombinaciji s glukoza izomerazom.
10. 5-D-fruktoza dehidrogenaza za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačena time što je 5-D-fruktoza dehidrogenaza u kombinaciji s invertazom i / ili multazom.
11. 5-D-fruktoza dehidrogenaza za uporabu u skladu s patentnim zahtjevom 1, naznačena time što je navedena 5-D-fruktoza dehidrogenaza prisutna u humano-nestabilnom pripravku tvari prilagođenog za oralnu primjenu, koja sadrži kapsulu koja sadrži 5-D-fruktozu dehidrogenazu.
12. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 11, naznačena time, da je navedeni sastav tvari u obliku jedinične doze, a navedena jedinična doza sadrži između 10 i 5 milijuna jedinica aktivnosti 5-D-fruktoze dehidrogenaze.
13. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 12, naznačena time, da jedinična doza sadrži između 25 i 2,5 milijuna jedinica aktivnosti 5-D-fruktoze dehidrogenaze.
14. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 12, naznačena time, da jedinična doza sadrži između 50 i 1 milijun jedinica aktivnosti 5-D-fruktoze dehidrogenaze.
15. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 11, naznačena time, da spomenuti sastav tvari također sadrži glukoza izomerazu.
16. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 1, naznačena time, da spomenuta upotreba sadrži terapijsku metodu snižavanja bioraspoloživosti fruktoze u ljudskom ili životinjskom tijelu.
17. 5-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 1, naznačena time, da je navedena 5-D-fruktoza dehidrogenaza u kombinaciji s glukoza izomerazom, a navedena kombinacija se upotrebljava u terapijskoj metodi smanjenja bioraspoloživosti fruktoze u ljudskom ili životinjskom tijelu.
HRP20180327TT 2005-11-16 2018-02-22 Sredstva za uporabu u slučaju intolerancije na fruktozu HRP20180327T1 (hr)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
DE102005055081 2005-11-16
DE102005056169 2005-11-23
DE102005060769 2005-12-16
DE102005060768 2005-12-16
DE102006000881 2006-01-04
DE102006000873 2006-01-04
DE102006001015 2006-01-05
US75741406P 2006-01-10 2006-01-10
US75742406P 2006-01-10 2006-01-10
DE102006012244A DE102006012244A1 (de) 2005-11-16 2006-03-15 Mittel zur Anwendung bei Fructoseintoleranz
DE102006013624A DE102006013624B4 (de) 2005-11-23 2006-03-22 Mittel zur Anwendung bei Fructoseintoleranz
DE102006014423 2006-03-27
US83105006P 2006-07-17 2006-07-17
US83117406P 2006-07-17 2006-07-17
EP06820896.6A EP1951290B1 (en) 2005-11-16 2006-11-15 Agent for use in the case of fructose intolerance
PCT/IB2006/003223 WO2007057749A2 (en) 2005-11-16 2006-11-15 Agent for use in the case of fructose intolerance

Publications (1)

Publication Number Publication Date
HRP20180327T1 true HRP20180327T1 (hr) 2018-04-06

Family

ID=38049014

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180327TT HRP20180327T1 (hr) 2005-11-16 2018-02-22 Sredstva za uporabu u slučaju intolerancije na fruktozu

Country Status (13)

Country Link
US (3) US20090081300A1 (hr)
EP (2) EP3318271A1 (hr)
JP (1) JP2009519897A (hr)
KR (1) KR20080080122A (hr)
AU (1) AU2006314188B2 (hr)
CA (1) CA2669431C (hr)
CY (1) CY1119940T1 (hr)
HR (1) HRP20180327T1 (hr)
IL (1) IL191363B (hr)
PL (1) PL1951290T3 (hr)
SI (1) SI1951290T1 (hr)
WO (1) WO2007057749A2 (hr)
ZA (1) ZA200805143B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013211517B2 (en) * 2005-11-23 2016-06-30 Pro Natura Gesellschaft Fur Gesunde Ernahrung Mbh Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
JP2009519900A (ja) * 2005-11-23 2009-05-21 プロ・ナトゥーラ・ゲゼルシャフト・ヒューア・ゲズンデ・エルネールング・ミット・ベシュレンクテル・ハフツング 特に、脂肪過多症（肥満）の症例での使用のための、食物の有効カロリー量を減少させるための、および治療的体重減少のための薬剤
DE102007008664B4 (de) 2007-02-20 2021-07-29 Vitacare Gmbh & Co. Kg Mittel zur Anwendung bei Fructoseintoleranz
PL2340035T3 (pl) 2008-09-04 2015-02-27 Stada Arzneimittel Ag Leczenie upośledzenia wchłaniania fruktozy
EP2161034A1 (de) 2008-09-04 2010-03-10 Sciotec Diagnostic Technologies GmbH Behandlung von Fruktose-Malabsorption
WO2010107414A1 (en) * 2009-03-19 2010-09-23 Amano Enzyme Inc. Enzyme compositions and use thereof
EP3415631A1 (en) 2017-06-13 2018-12-19 RWTH Aachen Methods of producing 5-ketofructose
KR20220007660A (ko) * 2019-05-13 2022-01-18 새미-사빈사 그룹 리미티드 프럭토필릭 락트산 생산 박테리아
CN112536005B (zh) * 2020-11-05 2022-05-03 华南理工大学 一种淀粉包埋香气物质微胶囊及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107291A (en) * 1969-06-05 1978-08-15 Sankyo Company Limited Compositions for cleaning teeth and oral cavity
US4396602A (en) * 1981-09-22 1983-08-02 Asahi Kasei Kogyo Kabushiki Kaisha Blood glucose level lowering agents
DK8502857A (hr) * 1984-06-25 1985-12-26
JPS6236191A (ja) * 1985-08-09 1987-02-17 House Food Ind Co Ltd 固定化酵素の製造方法
SE8505783D0 (sv) 1985-12-06 1985-12-06 Rolf Bergkvist Forfarande for framstellning av livsmedelsprodukter och dessas anvendning
JPH0640824B2 (ja) * 1987-03-19 1994-06-01 東洋紡績株式会社 安定なフラクト−スデヒドロゲナ−ゼ組成物
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
FI905402A (fi) 1990-11-01 1992-05-02 Alko Ab Oy Oligosackaridblandning och foerfarande foer dess efterbehandling.
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5759539A (en) * 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
US6057139A (en) * 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
BR9810171A (pt) * 1997-06-17 2001-11-06 Monsanto Co Expressão de frutose 1,6 bisfosfato aldolase em plantas transgênicas
AU740108B2 (en) 1997-06-17 2001-11-01 Novozymes A/S An oral care composition comprising a bacillus pullulanase and a dextranase
US6306445B1 (en) * 1998-05-13 2001-10-23 Novozymes Biotech Inc. Methods for using dehydrogenases in baking
CA2328137A1 (en) * 1998-05-29 1999-12-09 Novo Nordisk A/S Methods for using xyloglucan endotransglycosylase in baking
US6042823A (en) 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
JP2000125883A (ja) * 1998-10-21 2000-05-09 Internatl Reagents Corp フルクトキナーゼ及びその遺伝子
WO2000027215A1 (en) 1998-11-05 2000-05-18 Novozymes A/S Methods for using a glucose isomerase in baking
AU772153B2 (en) * 1999-02-12 2004-04-08 Molecular Insight Pharmaceuticals, Inc. Matrices for drug delivery and methods for making and using the same
EP1203822A1 (en) * 2000-11-02 2002-05-08 Societe Des Produits Nestle S.A. Extracellular polysaccharide from Gluconacetobacter spp
US6754884B1 (en) 2001-07-02 2004-06-22 Bea Systems, Inc. Programming language extensions for processing XML objects and related applications
JP4824886B2 (ja) * 2001-09-11 2011-11-30 長岡香料株式会社 フルクトース吸収阻害剤、組成物、および食品
US20030113310A1 (en) * 2001-12-17 2003-06-19 Van Laere Katrien Maria Jozefa Method for the treatment of obesity, overweight and fluctuations in blood insuline and/or glucose levels
DK1553848T3 (da) * 2002-10-11 2008-01-21 Novozymes As Fremgangsmåde til fremstilling af et varmebehandlet produkt
JP2004261174A (ja) * 2003-02-13 2004-09-24 Fujicco Co Ltd 豆乳発酵物およびそれを用いた飲食品
US20060269826A1 (en) 2003-03-03 2006-11-30 Eugenii Katz Novel electrode with switchable and tunable power output and fuel cell using such electrode
KR20070039924A (ko) * 2004-07-05 2007-04-13 마루킨 바이오 가부시키 가이샤 석류액, 석류액 분말 및 분말 생산 공정
JP2009519900A (ja) * 2005-11-23 2009-05-21 プロ・ナトゥーラ・ゲゼルシャフト・ヒューア・ゲズンデ・エルネールング・ミット・ベシュレンクテル・ハフツング 特に、脂肪過多症（肥満）の症例での使用のための、食物の有効カロリー量を減少させるための、および治療的体重減少のための薬剤

Also Published As

Publication number Publication date
US20130224171A1 (en) 2013-08-29
US20180344818A1 (en) 2018-12-06
CA2669431A1 (en) 2007-05-24
WO2007057749A3 (en) 2008-10-16
CA2669431C (en) 2019-04-23
WO2007057749A2 (en) 2007-05-24
US20090081300A1 (en) 2009-03-26
EP1951290B1 (en) 2017-12-27
CY1119940T1 (el) 2018-12-12
EP1951290A4 (en) 2009-03-11
JP2009519897A (ja) 2009-05-21
US9446101B2 (en) 2016-09-20
ZA200805143B (en) 2012-02-29
US10568942B2 (en) 2020-02-25
PL1951290T3 (pl) 2018-05-30
EP1951290A2 (en) 2008-08-06
EP3318271A1 (en) 2018-05-09
AU2006314188A1 (en) 2007-05-24
AU2006314188B2 (en) 2014-01-16
IL191363B (en) 2018-05-31
SI1951290T1 (en) 2018-04-30
KR20080080122A (ko) 2008-09-02

Similar Documents

Publication Publication Date Title
HRP20180327T1 (hr) Sredstva za uporabu u slučaju intolerancije na fruktozu
WO2006123248A3 (en) Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
NO20084199L (no) Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom
WO2008085484A3 (en) Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
ECSP056076A (es) Sistema de suministro para droga y terapia celular
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
NO20080244L (no) Doseringsstyring for prasugrel
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2005087255A3 (en) Method of optimizing treatment with interferon-tau
BRPI0507733A (pt) composição para a liberação de um agente hipnótico através da mucosa oral, e, método para tratar um distúrbio do sono em um paciente em necessidade deste
BRPI0602179A (pt) composição farmacêutica compreendendo ciclobenzaprina e aceclofenaco em combinação
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
TWM478502U (zh) 一種使老舊細胞透過鈉鉀離子通道排出而達到細胞活化功效之蕉科植物與仙人掌萃取物包埋結構
MD3381G2 (ro) Metodă de tratament al parotiditei cronice la copii
ZA200501028B (en) Administration of externally administered treatment substances to animals